EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma

Michael LaPelusa, Shadi Chamseddine, Hop Sanderson Tran Cao, Lianchun Xiao, Elshad Hasanov, Priya Bhosale, Hesham M Amin, Yehia I Mohamed, Betul Gok Yavuz, Yara Sakr, Li Xu, Ian Hu und 11 weitere

Oncology · 2024

DOI: 10.1159/000541250 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Oncology, 2024. Verfasst von Michael LaPelusa und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mblapelusa@mdanderson.org. Hauptthemen laut MEDLINE: Nivolumab, Liver Neoplasms, Carcinoma, Hepatocellular, Ipilimumab. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Perioperative immunotherapy has shown promise in some patients with early-stage hepatocellular carcinoma (HCC). This study examined tissue and imaging biomarkers associated with pathologic response in a phase II clinical trial in patients with resectable HCC.

Methods

Analysis included 18 patients with biopsy-proven resectable HCC treated with neoadjuvant nivolumab plus ipilimumab or nivolumab alone in a phase II clinical trial at MD Anderson Cancer Center (NCT03222076). Liver MRE (to measure tissue fibrosis) and biopsies (to evaluate immune activation markers) were obtained serially pretreatment and after completing neoadjuvant immunotherapy. A major pathologic response (MPR) was defined as tumor necrosis of more than 70%. Data comparing patients with MPR versus those without were summarized using descriptive statistics and compared using the Wilcoxon rank-sum test.

Results

Patients with MPR after neoadjuvant immunotherapy tended to have larger tumors (mean 9.52 vs. 4.99 centimeters; p = 0.050). They had a significant reduction in tumor size posttreatment (14.67% reduction vs. 9.15% increase in size; p = 0.042) and a nonsignificant decrease in serum AFP (−24.20% vs. −14.00%; p = 0.085). Further, patients with MPR had a greater increase in intratumoral expression levels of CD8 (26.92% vs. −0.04%; p = 0.026), granzyme B (15.56% vs. −2.24%; p = 0.011), and PD-1 (20.17% vs. 0.40%; p = 0.048) but not PD-L1 (7.69% vs. 0.57%; p = 0.26). For imaging biomarkers, tumor and liver fibrosis were comparable before and after neoadjuvant therapy in patients with MPR versus nonresponders.

Conclusion

Changes in tumor size, immune cell infiltration, and immune cell activation are candidate predictive markers of pathologic response to neoadjuvant immunotherapy in patients with resectable HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabLiver NeoplasmsCarcinoma, HepatocellularIpilimumabAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleNeoadjuvant TherapyMiddle AgedAgedBiomarkers, TumorAdultTreatment Outcome

Stichwörter der Autor:innen

Hepatocellular carcinomaNeoadjuvant immunotherapy

Substanzen

NivolumabIpilimumabBiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mblapelusa@mdanderson.org.
  • Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • The Ohio State University Comprehensive Cancer Center - The James, Columbus, Ohio, USA.
  • Department of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

LaPelusa, M., Chamseddine, S., Tran Cao, H. S., Xiao, L., Hasanov, E., Bhosale, P., Amin, H. M., Mohamed, Y. I., Gok Yavuz, B., Sakr, Y., Xu, L., Hu, I., Lee, S. S., Sakamuri, D., Jindal, S., Nguyen, V., Curran, M. A., Sun, R., Rashid, A., …, & Kaseb, A. O. (2024). Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma. Oncology. https://doi.org/10.1159/000541250

Vancouver

LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, et al. Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma. Oncology. 2024. doi:10.1159/000541250

BibTeX
@article{LaPelusa2024,
  author = {LaPelusa, Michael and Chamseddine, Shadi and Tran Cao, Hop Sanderson and Xiao, Lianchun and Hasanov, Elshad and Bhosale, Priya and Amin, Hesham M and Mohamed, Yehia I and Gok Yavuz, Betul and Sakr, Yara and Xu, Li and Hu, Ian and Lee, Sunyoung S and Sakamuri, Divya and Jindal, Sonali and Nguyen, Van and Curran, Michael A and Sun, Ryan and Rashid, Asif and Duda, Dan Gabriel and Sharma, Padmanee and Qayyum, Aliya and Kaseb, Ahmed Omar},
  title = {Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000541250}
}
Kostenlos starten →